Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer

Serum CA 19‐9 is the only FDA approved biomarker recommended for use in the routine management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies related to pancreatic cancer appear in the literature, highlighting the need to discover and develop improved tests. Diagnostic bioma...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of surgical oncology 2013-01, Vol.107 (1), p.15-22
Hauptverfasser:	Winter, Jordan M., Yeo, Charles J., Brody, Jonathan R.
Format:	Artikel
Sprache:	eng
Schlagworte:	biomarkers Biomarkers, Tumor - metabolism CA-19-9 Antigen - blood Carcinoma, Pancreatic Ductal - metabolism Carcinoma, Pancreatic Ductal - pathology DNA, Neoplasm - analysis Humans Pancreatic cancer pancreatic ductal adenocarcinoma Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology predictive markers Prognosis prognostic markers Proteome - analysis Sensitivity and Specificity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Serum CA 19‐9 is the only FDA approved biomarker recommended for use in the routine management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies related to pancreatic cancer appear in the literature, highlighting the need to discover and develop improved tests. Diagnostic biomarkers have implications for early detection of PDA, prognostic markers predict patient survival and recurrence patterns, and predictive markers can help personalize treatment regimens. J. Surg. Oncol. 2013;107:15–22. © 2012 Wiley Periodicals, Inc.
ISSN:	0022-4790 1096-9098
DOI:	10.1002/jso.23192